NSCLC

This study tested a new drug called JAB-21822, taken as a pill, in 29 adults with advanced solid tumors (like lung or colon cancer) that have a specific KRAS G12C mutation. The goal was to see if the drug is safe and can shrink tumors. Participants had already tried at least one …

This study tested a drug called furmonertinib in 24 adults with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that had spread to the brain. The goal was to see how well the drug controlled brain tumors and how safe it was. Participants took the drug and were monitor…

This phase 3 trial tested a wearable device called Tumor Treating Fields (TTFields) in 291 people with stage 4 non-small cell lung cancer that had worsened after platinum chemotherapy. The device delivers low-intensity electric fields to the tumor area and was used alongside stan…

This study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 adults with advanced non-small cell lung cancer or head and neck cancer that had not responded to prior treatment. The goal was to see if the combo could shrink tumors safely. …

This study tested a combination of three drugs (afuresertib, sintilimab, and chemotherapy) in 22 adults with solid tumors like lung, cervical, or stomach cancer that had stopped responding to prior immunotherapy. The goal was to find the safest dose and see if the combo could shr…

This study tested whether adding bevacizumab to erlotinib works better than erlotinib alone for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR gene mutations. About 311 Chinese adults took part. The goal was to see if the combination could delay can…

This study looked at whether a targeted treatment called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows rising levels of cancer DNA (minimal residual disease or MRD). 37 participants received LAT to all visible …

This early-stage study tested a new drug called CFT1946 in 89 adults with advanced solid tumors that have a specific BRAF V600 gene change. The goal was to find safe doses and see if the drug, given alone or with other medicines, can shrink tumors. The study focused on safety and…

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested a breath analysis device (eNose) to see if it can predict which cancer patients will benefit from immunotherapy. Researchers collected breath samples from 190 adults with lung, melanoma, bladder, kidney, or head and neck cancers before treatment. The goal was to…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…

This study looked at 3000 people with advanced non-small cell lung cancer to see if a combination of chest CT scans, lung function tests, and blood markers could predict how well immunotherapy plus chemotherapy works and who might develop a serious lung inflammation called pneumo…